Menopause, Postmenopausal Estrogen Preparations, and the Risk of Adult-Onset Asthma. A Prospective Cohort Study

Rebecca Troisi, F E Speizer, Walter C. Willett, D. Trichopoulos, Bernard Rosner

American Journal of Respiratory and Critical Care Medicine · 1995 · 384 citations · 0 references

Concepts

TL;DR

The study examined whether hormone replacement therapy influences asthma incidence in women aged 34–68. The cohort followed 582,135 person‑years from 1980 to 1990, documenting 726 new asthma cases. Never users of postmenopausal hormones had a 35 % lower asthma risk than premenopausal women, whereas ever use of hormone therapy increased risk by 49 %, with longer duration and higher doses further elevating risk.

Abstract

We prospectively evaluated the association of hormone replacement therapy and asthma incidence in a cohort of pre- and postmenopausal women 34 to 68 yr of age. During 582, 135 person-years of follow-up between 1980 and 1990, 726 new cases of asthma were documented. Postmenopausal women who were never users of replacement hormones had a significantly lower age-adjusted risk of asthma than premenopausal women (relative risk = 0.65; 95% confidence interval [CI] = 0.46 to 0.92). Among naturally menopausal women, the age-adjusted relative risk of asthma for ever use of postmenopausal hormones was 1.49 (95% CI = 1.10 to 2.00); for current use of hormones (conjugated estrogens with or without progesterone), 1.50 (95% CI = 0.98 to 2.30); and for past use, 1.52 (95% CI = 1.08 to 2.13), compared with never use of hormones. Ever users of 10 or more years' duration had twice the age-adjusted risk of asthma compared with women who never used postmenopausal hormones (95% CI = 1.39 to 2.87). Among current users of conjugated estrogens, there was a positive dose-response demonstrated between daily dose and asthma risk (p for trend = 0.007). While confirmatory studies are warranted, these data suggest that estrogen plays a role in the pathophysiology of asthma and that long-term use and/or high doses of postmenopausal hormone therapy increase subsequent risk of asthma.